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Abstract
Purpose To review the currently available literature reporting the patterns of recurrence and their predictive factors after 
open radical cystectomy (RC) for bladder cancer.
Methods A review of the literature was performed using the MEDLINE, Scopus and Web of Sciences databases from Janu-
ary 1997 to May 2017. The PRISMA guidelines were followed for the conduct of the study.
Results Local recurrence rate ranges between 30 and 54%. Distant recurrence is not often standardized and is reported in up 
to 50% of cases. The overall 5-year recurrence-free survival rates from 58 to 81%. The mean follow-up of studies included 
in the analysis ranged from 18 to 350 months. Details on the most important demographic and epidemiological, clinical, 
histologic and pathologic predictors of recurrence after radical cystectomy are provided through an evidence-based approach. 
The impact of the extension of lymph node dissection on recurrence after RC is investigated.
Conclusions A correct prognostic assessment is essential for patients undergoing radical cystectomy for bladder cancer, 
thereby potentially improving their oncologic outcomes.
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Adjuvant chemotherapy
Electronic supplementary material The online version of this 
article (https://doi.org/10.1007/s00345-017-2115-4) contains 
supplementary material, which is available to authorized users.
 * Shahrokh F. Shariat 
 shahrokh.shariat@meduniwien.ac.at
1 Department of Urology, University of Florence, Careggi 
Hospital, Florence, Italy
2 Department of Urology, Medical University of Vienna, 
Vienna, Austria
3 Division of Oncology/Unit of Urology, IRCCS San Raffaele 
Hospital, URI, Milan, Italy
4 Department of Urology, Institut Jules Bordet, Université 
Libre de Bruxelles, Bruxelles, Belgium
5 Division of Urology, Department of Special Surgery, Jordan 
University Hospital, The University of Jordan, Amman, Jordan
6 Department of Urology and Pediatric Urology, 
Julius-Maximilians-University of Würzburg, Würzburg, 
Germany
7 Karl Landsteiner Institute of Urology and Andrology, 
Vienna, Austria
8 Department of Urology, University of Texas Southwestern 
Medical Center, Dallas, TX, USA
9 Department of Urology, Weill Cornell Medical College, 
New York, NY, USA
10 Department of Urology and Comprehensive Cancer Center, 
Vienna General Hospital, Medical University of Vienna, 
Währinger Gürtel 18-20, 1090 Vienna, Austria
Introduction
Bladder cancer (BC) is the 9th most commonly diagnosed 
cancer and is ranked 13th for cancer deaths in the overall 
population in 2015 worldwide. Approximately 30% of 
newly diagnosed bladder cancer patients present with 
muscle-invasive BC (MIBC) disease with 10–15% of 
cases already metastatic at diagnosis. The risk of progres-
sion for high-risk non-MIBC after 5 years is 45% [1]. The 
standard treatment for patients with clinically localized 
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(cT2-T4a N0M0) MIBC is radical cystectomy (RC) with 
bilateral pelvic lymph node dissection (PLND). The use 
of neoadjuvant chemotherapy (NAC) may be a valid 
option for MIBC but its benefit is still debated. In addi-
tion, it is reasonable to propose immediate RC to those 
patients with non-MIBC at highest risk of progression. 
Furthermore, early RC should be offered to all patients 
with non-MIBC failing endovesical therapy [1].
Unfortunately, a significant proportion of patients with 
MIBC experiences recurrence and eventually death after 
RC. There is no definitive evidence regarding the recur-
rence rate after RC. In particular, the definition of local 
and distant recurrence is not standardized, the recurrence-
free survival (RFS) is highly variable and the specific 
timing of recurrence is not well defined across the pub-
lished series [2–5]. Several factors have been variously 
associated with recurrence after RC. However, the differ-
ent patient selection and the variable use of preoperative 
treatments among studies could affect the impact on the 
analysis of predictors of recurrence after RC.
Under this light, we aimed to review the currently 
available literature reporting the patterns of recurrence 
and their predictive factors after open RC. Moreover, we 
critically assessed the current limitations of the published 
series outlining potential implications for future research.
Materials and methods
A comprehensive review of the English-language litera-
ture was performed using the MEDLINE, Scopus and 
Web of Sciences databases from January 1st, 1997 to May 
1st, 2017 following the preferred reporting items for sys-
tematic reviews and meta-analyses (PRISMA) statement 
using the following keywords: “recurrence” or “relapse” 
or “metastasis” and “bladder cancer” or “urothelial blad-
der cancer” and “radical cystectomy” (Fig. 1). After a 
first screening based on study title and abstract, all papers 
were assessed based on full text and excluded with rea-
sons when appropriate. Two reviewers (A.M. and R.C.) 
carried out this process independently. Disagreement 
was solved by a third party (G.H.). The list of articles 
that were judged to be highly relevant by these authors 
was reviewed by all coauthors until a final consensus was 
reached on the articles included in the analysis. The “risk-
of-bias” evaluation of the studies included to investigate 
the recurrence rate (n = 48) was assessed according to the 
Cochrane Handbook for Systematic Reviews of Interven-
tions [6].
Evidence synthesis
A total of 1481 articles were identified. After exclusion of 
duplicates, case reports, congress abstracts, editorials and 
papers with topics that were not specific for this review, 
1125 papers were selected for full-text assessment of eligi-
bility. After full-text evaluation, 355 studies were included 
for the analysis of predictors of recurrence in patients treated 
with radical cystectomy. Of these, 48 studies were included 
for the assessment of recurrence rate (Fig. 1).
Type of studies and quality of the evidence
For the analysis of the predictors of recurrence, 313 studies 
were retrospective, 14 were prospective and 27 were rand-
omized clinical trials (RCTs). Sample size ranged between 
33 and 9064 patients. Most series involved multiple sur-
geons. For the analysis of recurrence rate, 29 studies were 
retrospective, 3 were prospective and 16 were RCTs. Sample 
size ranged between 110 and 9064 patients. Risk of bias 
evaluation is summarized in Supplementary Table 1.
Definition and controversies
EAU Guidelines defined local recurrence after RC as any 
recurrence that takes place in soft tissues at the original sur-
gical site or lymph nodes (LN) in the area of PLND [1]. Data 
in literature are very inconsistent, as a detailed discrimina-
tion between local and distant recurrence is not always pre-
sent. Similarly, the percentages of RFS are highly variable 
even across large surgical series. Moreover, some studies 
include different neoadjuvant or adjuvant chemotherapy 
(AC) regimens, which may hinder the overall interpretation 
of surgical series.
Recurrence rates in patients treated with open RC
In a retrospective study involving 4118 patients naïve of 
NAC treated at several institutions, the RFS was 63, 60 and 
57% at 3, 5 and 10 years, respectively [2]. Xylinas et al. [3] 
analyzed the oncologic outcomes of 2145 patients naïve of 
NAC treated at European and US institutions with open RC 
for pT1-T3N0 urothelial BC. The RFS was 68% at a median 
follow-up of 48 months. Similarly, Zehnder et al. reported 
the oncologic outcomes of 1488 patients at a median follow-
up of 162 months [4]. Overall, 6% received NAC and 3% 
preoperative radiotherapy (RT). The 5- and 10-year RFS 
were 68 and 64%, respectively, with a time to recurrence 
ranged from 0 to 29.2 years.
The recurrence rates in patients treated with NAC and 
open RC are still undetermined. In most of the retrospec-
tive studies, a low percentage of patients receive NAC 
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due to the contraindications and the underuse reported in 
several centers. The best shreds of evidence come from 
RCTs, even if the real number of patients effectively sub-
mitted to the combined therapy is difficult to estimate due 
to the variable number of patients declining NAC and of 
those not completing the full number of cycles for adverse 
events.
In the experimental arm from the BA06 30894 (Inter-
national Collaboration of Trialists) RCT, 491 BC patients 
with T2-4N0-xM0 stage underwent NAC (cisplatin, metho-
trexate, and vinblastine) and radical treatment (50% RC, 
Records identied through MEDLINE, Web of Science and Scopus databases:
Search Query: 
1) (recurrence OR relapse OR metastasis) AND (((urothelial AND (carcinoma OR
cancer)) AND bladder) AND (open radical cystectomy);
2) (recurrence OR relapse OR metastasis) AND (((urothelial AND (carcinoma OR
cancer)) AND bladder) AND cystectomy
Filters: English language, 1997-2017
(n = 1460)
gnineercS
dedulcnI
ytilibigilE
noitacifitnedI
Additional records 
idenfied from reference 
lists of original arcles and 
review arcles and from 
further up-to-date 
literature search
(n = 21)
Records screened after 
duplicates removed
(n = 1318)
Records excluded after ti tle and abstract 
review (n = 193)
- Not specific to the topics of the review 
(n = 124)
- Meeng abstracts, case reports, editorials
(n = 69)
Full-text articles assessed 
for eligibility
(n = 1125)
Studies included for the analysis of predictors 
of recurrence in patients treated with radical 
cystectomy.
(n = 355)
Articles excluded after full-text evaluation 
(n = 771)
- Systemac or collaborave reviews, meta-
analyses, consensus-conference papers (n=136)
- Studies reporng laparoscopic and/or robot 
assisted radical cystectomy series (n=124)
- Insufficient relevance for the topic of this review, 
lack of data reporng and studies with short 
follow-up (n=510)
Studies included for assessment of 
recurrence patterns.
(n = 48)
Articles excluded after full-text evaluation 
for assessment of recurrence rate (n = 306)
- Studies analysing subcohorts of paents selected 
for epidemiological characteriscs (n=54), for 
clinical characteriscs (n=46), for operave 
techniques (n=8) and for pathologic features at 
radical cystectomy specimen (n=198).
Fig. 1  Flow chart for article selection process
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42% radical RT and 8% preoperative RT plus RC) [7]. The 
median locoregional disease-free and metastasis-free sur-
vival for the group were 23 months (47% at 3 years) and 
32 months (45% at 3 years). In the Southwest Oncology 
Group (SWOG) RCT, 153 patients with T2-4N0M0 stage 
BC were randomly assigned to methotrexate, vinblastine, 
doxorubicin, and cisplatin (MVAC) NAC and subsequent 
RC [8]. At 5 years, 57% of the patients were alive. After 
a median follow-up of 8.7 years, 35% of patients died of 
disease. In a meta-analysis, the oncologic outcomes of 2491 
patients treated with NAC and radical treatment (RC, radi-
cal RT, or preoperative RT and RC) from 10 clinical RCTs 
were reported. The locoregional disease-free survival was 
166/217 (76.5%) and 1232/1963 (62.8%) in patients treated 
with single agent platinum and platinum-based combina-
tion, respectively. The metastasis-free survival rate was 
154/217 (71%) and 1181/1963 (60.2%) in patients treated 
with single agent platinum and platinum-based combina-
tion, respectively.
According to the studies included in this review, the 
reported local recurrence rate after open RC was between 
29.9 and 53.8%, and the 5-year RFS rates from 58 to 80.9%. 
The median follow-up of studies included in the analysis 
ranged from 18 to 350 months.
Predictive factors of recurrence‑free survival 
in patients treated with open RC
Demographic and epidemiologic characteristics
Although men are three to four times more likely to develop 
BC, several epidemiologic reports associated female gender 
with a more advanced disease and worse survival rates [9, 
10]. Messer et al. [11] confirmed that female gender, after 
adjusting to standard clinical and pathologic features, was 
associated with an increased risk for cancer-specific mortal-
ity (CSM) and disease recurrence compared to male gender 
in patients undergoing open RC. In other studies, gender 
was not associated with outcomes in stage-adjusted analyses, 
whereas pathologic tumor stage remained the most powerful 
factor influencing the course of disease in both genders [12].
Elderly patients have more years to compound comorbidi-
ties. As such, they are associated with higher mortality after 
RC [13]. In a retrospective analysis of 605 patients treated 
with open RC, Horovitz et al. reported that octogenarians 
had comparable RFS to the younger counterparts [14]. 
Conversely, an overview of the Bladder Cancer Research 
Consortium reported that patients aged > 80 years had a 
significantly greater risk of disease recurrence than patients 
aged ≤ 60 years [15]. However, the retrospective nature of 
the studies suffered of the selection bias related to the higher 
use of bladder-sparing techniques in older patients and to the 
lower use of both NAC and AC.
In a retrospective multicentre study on more than 1500 
patients, current smoking status and high cumulative smok-
ing exposure at the time of RC was significantly associated 
with advanced tumor stage, nodal metastasis, disease recur-
rence, and CSM in patients treated with RC for high-risk 
non-MIBC and MIBC [16]. Smoking cessation > 10 years 
prior to RC mitigates the detrimental effect of smoking. 
Conversely, in two different studies, smoking was not an 
independent predictor of RFS [17, 18]. In addition, smok-
ing seemed to affect survival only among men, but not in 
women, who had overall a poorer survival compared to the 
male gender [17]. The most important studies of this para-
graph are summarized in Table 1.
Clinical characteristics
Several serological parameters have been investigated as 
possible predictors of recurrence in patients treated with 
open RC for MIBC. The pre-treatment neutrophil-to-lym-
phocyte ratio (NLR) is an emerging marker of host inflam-
mation. Several studies reported the impact of NLR on onco-
logic outcomes in patients undergoing RC. The threshold 
varied among studies (from 2, 7 to 3). NLR was significantly 
associated with extravesical tumor extension, node involve-
ment and was an independent predictor of relapse and CSM 
after RC [19, 20]. Similarly, the lymphocyte-to-monocyte 
ratio (LMR), an alternative marker of inflammation, was 
significantly associated with RFS [19, 21]. Preoperative 
hypoalbuminemia (< 3.5 g/dL) [22] and low albumin/globu-
lin ratio (≥ 1.60) [23] were found to be independent predic-
tors of RFS and OS, and RFS and cancer-specific survival 
(CSS),  respectively. Moreover, the low albumin/globulin 
ratio remains an independent predictor of RFS and CSS even 
in a subcohort of patients with normal serum albumin [23].
In a retrospective analysis of 906 treated with RC, throm-
bocytosis (defined as > 400,000 platelets/mcl) was signifi-
cantly associated with adverse pathologic disease stage and 
LN involvement [24]. Thrombocytosis was independently 
associated with OS, but not with RFS, after adjusting for 
clinicopathological factors.
A recent meta-analysis analyzed 11 and 7 studies evaluating 
the impact of anemia and hemoglobin level as continuous vari-
able, respectively, in patients treated with RC. Both anemia and 
hemoglobin level were independently associated with increased 
all-cause mortality, CSM and disease recurrence [25].
The AB0 blood group antigen was found to be associated 
with a higher tumor stage, but not a higher risk of relapse 
in patients treated with RC [26]. In a subanalysis of patients 
treated with AC after RC, the AB blood group antigen 
expression was significantly associated with a worse CSM 
compared to the A0, B0 and 00 blood groups [26].
The current evidence supports the prognostic role 
of inflammatory blood-based markers and physical 
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characteristics on oncologic outcomes after RC. Indeed, 
systemic inflammation seems to play a critical role in the 
pathogenesis of malnutrition. In a restricted cohort of 117 
Japanese patients, the prognostic nutritional index (PNI) 
but not the controlling nutritional status (CONUT) was sig-
nificantly associated with disease-specific survival after RC 
[27]. However, further studies are necessary to demonstrate 
the association between the preoperative nutritional status 
and oncologic outcomes in patients treated with RC for BC.
Patients with comorbidities are often less likely to have 
PLND and NAC [28]. Several studies reported that a higher 
comorbidity score was significantly associated with lower 
OS, but not RFS in patients undergoing open RC [29, 30]. 
However, after developing a recurrence, the presence of 
comorbidities was shown to have an independent correlation 
with lower survival [30]. A retrospective study including 
4118 patients treated with open RC showed that obesity was 
significantly associated with higher tumor grade, soft-tissue 
surgical margins (STSMs) and worse oncologic outcomes 
[2]. Other authors reported that a body mass index > 30 is an 
independent predictor of disease recurrence and CSM [31].
In patients with diabetes mellitus undergoing RC, dia-
betes mellitus was significantly associated with worse CSS 
[32]. Moreover, metformin use was related to a decreased 
risk of disease recurrence and CSM [32].
Clinical staging at transurethral resection (TUR) is a fun-
damental diagnostic and therapeutic tool for patients with 
BC [1, 33]. However, the clinical stage at TUR was shown to 
be divergent from pathologic tumor stage in more than a half 
of the reported cases [34]. Patients with clinical understag-
ing were associated with a higher risk of LN involvement at 
RC specimen and with worse CSM after RC [34].
In a retrospective evaluation of 297 patients treated with 
open RC without NAC, Culp et al. identified the presence 
of micropapillary or neuroendocrine features together with 
lymphovascular invasion (LVI) at TUR specimen, hydro-
ureteronephrosis and cT3b-T4a disease as readily assessable 
clinical factors to define a high-risk disease [35]. Patients with 
high-risk disease were found to have a higher probability of 
upstaging at RC specimen and to have a decreased disease-
specific and progression-free survival probabilities compared 
to low-risk patients. These results have been recently validated 
in an external cohort [36]. Indeed, this clinical preoperative 
risk grouping might help the decision-making process regard-
ing the administration of NAC [35, 36]. The most important 
studies of this paragraph are summarized in Table 2.
Histologic patterns
The prognostic value of pathologic features on recurrence is 
of great importance in patients treated with open RC. Lotan 
et al. [37] reported that LVI was an independent predictor of 
local, distant and overall recurrence in pN0 patients treated 
with open RC. Several studies unanimously confirmed that 
LVI at RC specimen has an independent association with 
RFS after surgery. In a report of 2000 patients, variant his-
tology (VH) of urothelial BC at bladder specimen accounts 
for approximately 25% of cases of patients undergoing RC 
[38]. Patients with VH had a significantly higher disease 
recurrence rate compared to those with pure urothelial BC 
patients or with squamous-cell differentiated BC. None-
theless, this effect did not remain significant on the mul-
tivariable model [38]. Soave et al. [39] demonstrated that 
the presence of VH and non-squamous cell differentiation 
had not a significant impact on oncological outcomes. Simi-
larly, Fairey et al. demonstrated that micropapillary vari-
ant of urothelial BC had similar oncological outcomes after 
open RC to those with pure urothelial BC after controlling 
for relevant clinical and pathologic factors [40]. Recently, 
Moschini et al. reported that pure VH, mostly represented 
by small-cell and micropapillary VH, compared to the pure 
urothelial BC at RC specimen was an independent pre-
dictor of CSM and RFS [41]. In a cohort of patients with 
cT1-4N0-2 treated with cisplatin-based NAC and RC, the 
squamous or glandular VH was an independent predictor of 
pathologic downstaging [42]. Furthermore, these patients 
presenting squamous or glandular VH had comparable over-
all survival compared to those with pure urothelial BC.
Contrasting results were reported regarding the impact of 
carcinoma in situ (CIS) at RC specimen on recurrence-free 
survival. In a retrospective evaluation, the clinical data of 
812 patients treated with RC were analyzed [43, 44]. The 
presence of concomitant CIS (46% of cases) was signifi-
cantly associated with urethra involvement at the pathologic 
specimen and, in patients with organ-confined disease, was 
independently associated with disease recurrence, but not 
bladder CSM [44]. Patients with CIS only at RC (12%) had 
no LN metastasis with durable control even in the case of 
failure after intravesical therapy [43]. The concomitant CIS 
was found to be an independent predictor of upper urinary 
tract carcinoma [45] Conversely in two other studies, con-
comitant CIS was not independently associated with sur-
vival outcomes [46, 47]. A recent analysis of 1128 patients 
undergoing RC without NAC evaluated the impact of CIS 
on survival outcomes [29]. The presence of CIS was inde-
pendently associated with CSM only in the subcohort of 
patients harboring an organ-confined disease. Patients with 
concomitant CIS had a significantly increased risk of devel-
oping urothelial recurrences regardless of the tumor stage 
[29]. The most important studies of this paragraph are sum-
marized in Supplementary Table 2.
Pathologic patterns, tumor and node stage
Positive STSMs seem to be significantly higher in patients 
with a non-organ-confined disease compared to ≤ pT2 cases 
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despite the surgical volume of the center [48, 49]. In a retro-
spective single-center study evaluating oncologic outcomes 
of 1589 patients treated with open RC, Dotan et al. showed 
that the most common locations were the posterior and lat-
eral walls of the bladder and the periprostatic soft tissue 
[49]. RFS was significantly higher in patients with posi-
tive compared to those with negative STSMs. The positive 
STSMs were independently associated with disease-specific 
death, but not with metastatic progression after adjusting 
for clinicopathological factors [49]. Patients with urethral 
positive surgical margin had an 18-fold higher risk of ure-
thral recurrence. In a multicentre overview of 154 patients 
with positive STSMs after RC, the local RFS and CSM was 
significantly lower in patients with positive urethral surgical 
margin [50]. However, at multivariable analysis the urethral 
margin was not an independent predictor of CSM.
Tumor and node stage at pathologic evaluation represent 
two powerful predictors of recurrence and CSM [1]. The 
International Bladder Cancer Nomogram Consortium ana-
lyzed the oncologic outcomes of 9064 patients treated with 
RC and lymphadenectomy, including 1550 patients with LN 
involvement [51]. The Authors developed a postoperative 
nomogram to predict the risk of recurrence. The pathologic 
tumor stage and grade and node status were found to have a 
direct correlation with the risk of recurrence. This associa-
tion was confirmed in other nomograms developed in wide 
international series [52, 53].
In a single-center retrospective study enrolling 1388 
patients, Umbreit et al. evaluated a multi-factorial, site-spe-
cific recurrence model in patients treated with open RC [54]. 
The abdominal/pelvic, upper urinary tract (UUT), thoracic 
and bone recurrence rate was 4.8, 28, 10.3 and 11%, respec-
tively. After adjusting for clinicopathological features, pT4 
stage, positive ureteral margins and multifocality were found 
to be independent predictors of upper tract recurrence. pT3 
and pT4 stage, lymph node invasion and multifocality were 
found to be independent predictors of abdominal/pelvic, tho-
racic and bone recurrence.
In a retrospective study involving 1600 patients treated 
with open RC at a tertiary referral center, extravesical tumor 
extension and LN density (ratio positive/total node at pathol-
ogy) greater than 4% were significantly associated with a 
higher recurrence rate [55]. Conversely, Tarin et al. analyzed 
the oncologic outcomes of 591 patients treated with open 
RC and PLND [56]. After adjusting for perioperative fea-
tures, the number of positive LN (none, 1, or 2 or more) 
was significantly associated with CSM. LN density was not 
a significant predictor of recurrence or CSS. RFS or CSS did 
not differ significantly between pN1, pN2, and pN3. Simone 
et al. [57] retrospectively identified the LN density cut-off 
values to predict CSS in 156 pN+ patients treated with RC 
and PLND. The thresholds were 11 and 30% for LN density, 
9 and 30 for LN count. In the present study, PLND was the 
greatest predictor of CSM.
Contrasting studies were reported regarding the influ-
ence of PLND extension on LN stage [57, 58]. However, 
the standard field of PLND should include the lymphatic 
tissue around the common iliac, external iliac, internal iliac 
artery, and obturator region. As crossover lymphatic drain-
age is very common, PLND should always be performed 
bilaterally [1].
Several studies hypothesized that an extended PLND 
(ePLND) up to the aortic bifurcation or even super-extended 
PLND (sePLND) up to the inferior mesenteric artery could 
be associated with better survival. May et al. [59] showed 
that the tumor-specific survival and the disease-free interval 
were improved when an ePLND with equal to or more than 
16 removed lymph nodes was performed. Zehnder et al. [60] 
conducted a retrospective bi-center cohort study on patients 
who underwent open RC and PLND with curative intent for 
pT2-3cN0M0 BC. In one institution, all patients were treated 
with an ePLND up to the mid-upper third of the common 
iliac vessels. In the other institution, all patients were treated 
with a sePLND. At multivariable analysis, after adjusting for 
Institution, pathological subgroup and AC, LN status and 
number of positive LNs were independent risk factors for 
RFS. The authors concluded that meticulous ePLND appears 
to provide survival and recurrence outcomes similar to those 
of sePLND [60]. However, no evidence is reported regard-
ing the possible oncologic benefits of sePLND in particular 
classes of patients such as those with a clinically suspicious 
LN involvement. The most important studies of this para-
graph are summarized in Supplementary Table 3.
Conclusions
A significant proportion of patients relapse after RC for 
MIBC. Local recurrence rate ranges between 30 and 54%. 
Distant recurrence is not often standardized and is reported 
in up to 50% of cases.
Higher age, female gender, and smoking exposure at the 
time of RC are the most relevant epidemiological predic-
tors of recurrence after RC. Preoperative higher NLR and 
lower hemoglobin are significantly associated with a worse 
RFS. Obesity is an independent predictor of RFS. The pres-
ence of micropapillary, neuroendocrine features and LVI at 
TUR specimen, hydroureteronephrosis and cT3b-T4a dis-
ease are clinical factors defining a high-risk disease, and 
are independent predictors of RFS after RC. Among the 
histologic patterns, LVI, pure VH and concomitant CIS 
have an independent correlation with RFS after open RC. 
Advanced tumor stage, multifocality, positive STSMs and 
LN involvement are the most relevant pathologic predictors 
of RFS after RC. A limited PLND resulted to be significant 
intraoperative predictors of recurrence. Better oncologic 
168 World Journal of Urology (2018) 36:157–170
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outcomes were reported in patients submitted to ePLND, 
while a sePLND seemed to not provide a significantly lower 
recurrence rate.
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